FAM89B

Across TCGA pan-cancer cohorts, FAM89B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM89B data layer compared with 20 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FAM89B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FAM89B expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where FAM89B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.788	0.922	.002	27	view →
LUAD	OS	Median	All	0.876	0.555	.005	10	view →
CCRCC	DFS	Tertile	IV	0.908	0.162	.024	10	view →
PDAC	OS	Median	All	0.450	0.587	.012	8	view →
GBM	OS	Tertile	All	0.305	0.619	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FAM89B–HNSC (OS)

Open the HNSC breakdown →